- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03044652
Investigation of Non-inferiority of Treatment of Vulvovaginal Dryness With WO2085 Moisturising Cream in Comparison to a Cream With 0.1% Estriol
July 11, 2017 updated by: Dr. August Wolff GmbH & Co. KG Arzneimittel
Prospective, Open-label, Multicenter, Multinational, Randomized Trial to Investigate the Non-inferiority of Treatment With WO2085 Moisturising Cream in Comparison to a Cream With 0.1% Estriol in a Panel of Post-menopausal Women Suffering From the Symptoms of Vulvovaginal Dryness in a Parallel Group Design
The aim of the study is to gain further experience with regard to the performance of the medical device WO2085 Moisturising Cream in comparison to a cream with 0.1% estriol.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
"Vaginal dryness" is defined as dryness, itching, burning and pain unrelated to sexual intercourse.
Study Type
Interventional
Enrollment (Actual)
172
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Aachen, Germany
- Dr. Gerick
-
Mölln, Germany
- Praxis für die Frau
-
Schenefeld, Germany
- proDERM Institute for Applied Dermatological Research
-
Schwarzenbek, Germany
- Praxis für die Frau
-
-
-
-
-
Bern, Switzerland
- Frauenklinik Inselspital Bern
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Post-menopausal women with the subjective symptoms of "vulvovaginal dryness" with a sum score (0-16) of the parameters dryness, itching, burning and pain unrelated to sexual intercourse of at least 3 AND a VAS value "Overall impairment of daily life due to the condition "vulvovaginal dryness" > 0 on Visit 1.
- Last menstruation more than 12 months before Visit 1 OR bilateral oophorectomy with or without hysterectomy more than 3 months before Visit 1.
- Physical and mental healthy women as assessed by the medical history.
- PAP test performed within the last 12 months before Visit 1 and result less than PAP III.
- Signed written informed consent before participation in the Trial.
- Willingness to actively participate in the trial and to come to the scheduled visits.
Exclusion Criteria:
- Known hypersensitivity against any of the ingredients of the test products.
- Any indication in the medical history regarding an impairment of the hepatic, renal, gastrointestinal, cardiovascular, pulmonary, endocrinological or hematological system (especially venous and arterial thromboembolism, ischemic stroke, myocardial infarction, porphyria) if clinically relevant for this clinical trial (cf. contraindications and warnings for Estriol cream 0.1%).
- Known thrombophilic disorders (e.g. protein C, protein S or antithrombin deficiency).
- Breast cancer (acute and / or in the medical history or suspected).
- Estrogen-dependent tumor (acute and / or in the medical history or suspected, especially ovarian and / or endometrial carcinoma).
- Systemic hormonal replacement therapy (tablets, patches, injections, dermal products), or phytohormonal therapy or use of SERMs (inter alia anti-estrogens) within 3 months before Visit 1 and / or during the conduct of this trial.
- Intrauterine device (IUD) with progestogen (Mirena®, Jaydess®)
- Pathological findings in cancer screening (Papanicolaou III, III D - V in the cervical test)
- Pathological changes in the vaginal or cervix area, which are caused by estrogen deficiency (except symptoms and condition of "vulvovaginal dryness"), e.g. diminution of labia caused by estrogen deficiency, constricted introitus.
- Patients with known infectious diseases (e.g. hepatitis or HIV infection).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Medical Device: WO2085 Moisturising Cream
WO2085 is a hormone-free Moisturizing Cream and is used to treat "vulvovaginal dryness" symptoms.
|
2.5 g of the investigational product WO2085 Moisturising Cream will be applied intravaginally, once daily in the evening.
After improvement of the symptoms the frequency may be reduced by the patient as needed.
In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day).
|
Active Comparator: Drug: Estriol Cream 0.1%
Estriol Cream 0.1% is a standard therapy for the treatment of vulvovaginal atrophy in postmenopausal women.
|
0.5 g of the reference product Estriol Cream 0.1% will be applied intravaginally once daily in the evening for the first 3 weeks.
Subsequently, the frequency will be reduced to twice a week for the last 3 weeks for all patients in this treatment group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline Total Severity Score of the Treatment of "vulvovaginal dryness" at 6 weeks.
Time Frame: Baseline, after 3 and 6 weeks
|
"Vulvovaginal dryness" will be measured by the Total Severity Score.
It is defined as the sum score of the single subjective symptom parameters dryness, itching, burning and pain unrelated to sexual intercourse, each scored from 0=none to 4=very severe.
In total a range of 0=no complaints to 16=very severe complaints is possible.
Differences to Baseline (Visit 1) of the Total Severity Score assessed after six weeks of treatment (Visit 3) serve as the primary endpoint for the test of non-inferiority.
|
Baseline, after 3 and 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall impairment of daily life
Time Frame: 6 weeks
|
Overall impairment of daily life due to the condition "vaginal dryness" (including subgroup analysis of patients with mild, moderate or severe impairment) will be measured by using a Visual Analogue Scale (VAS)
|
6 weeks
|
Global judgement of efficacy
Time Frame: 6 weeks
|
The global judgement of efficacy will be assessed by the investigator and the patient according to the following scale: 1=very good to 4=poor.
|
6 weeks
|
Global judgement of tolerability
Time Frame: 6 weeks
|
The global judgement of tolerability will be assessed by the investigator and the patient according to the following scale: 1=very good to 4=poor.
|
6 weeks
|
Adverse Events
Time Frame: after 3 and 6 weeks
|
Adverse events will be documented on Visits after 3 and 6 weeks, respectively (and in the patient diary, if applicable).
|
after 3 and 6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Director: Prof. Christoph Abels, MD, PhD, Dr. August Wolff GmbH & Co. KG Arzneimittel
- Principal Investigator: Prof. Petra Stute, MD, PhD, Universitätsklinik für Frauenheilkunde, Inselspital Bern
- Principal Investigator: Kirstin Deuble-Bente, MD, proDERM Institute for Applied Dermatological Research, Germany
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013 Sep;20(9):888-902; quiz 903-4. doi: 10.1097/GME.0b013e3182a122c2.
- Bachmann G. Urogenital ageing: an old problem newly recognized. Maturitas. 1995 Dec;22 Suppl:S1-S5. doi: 10.1016/0378-5122(95)00956-6.
- Biglia N, Peano E, Sgandurra P, Moggio G, Panuccio E, Migliardi M, Ravarino N, Ponzone R, Sismondi P. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol. 2010 Jun;26(6):404-12. doi: 10.3109/09513591003632258.
- Stute P, May TW, Masur C, Schmidts-Winkler IM. Efficacy and safety of non-hormonal remedies for vaginal dryness: open, prospective, randomized trial. Climacteric. 2015;18(4):582-9. doi: 10.3109/13697137.2015.1036854. Epub 2015 May 22.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2016
Primary Completion (Actual)
June 1, 2017
Study Completion (Actual)
June 1, 2017
Study Registration Dates
First Submitted
December 21, 2016
First Submitted That Met QC Criteria
February 2, 2017
First Posted (Estimate)
February 7, 2017
Study Record Updates
Last Update Posted (Actual)
July 14, 2017
Last Update Submitted That Met QC Criteria
July 11, 2017
Last Verified
July 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VFCr-12/2015
- 2016-002199-28 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vulvovaginal Atrophy
-
Nathura S.p.AEvidilya S.r.l.Recruiting
-
Koru Health GroupsCompletedVulvovaginal AtrophyTurkey
-
MadorraCompletedVulvovaginal AtrophyAustralia
-
Warner ChilcottCompletedVulvovaginal AtrophyUnited States
-
El. En. SpAStanford University; The Christ HospitalCompletedVulvovaginal AtrophyUnited States
-
PepTonic Medical ABCompletedVulvovaginal AtrophySweden
-
Faculdade de Medicina do ABCCompleted
-
Lee's Pharmaceutical LimitedActive, not recruitingPostmenopausal Vulvovaginal AtrophyChina
-
University of MessinaUniversity of Victoria; University of AthensCompletedMenopause | Vulvovaginal Atrophy
-
Venus ConceptCompletedVulvovaginal AtrophyItaly, Spain
Clinical Trials on WO2085 Moisturising Cream
-
Dr. August Wolff GmbH & Co. KG ArzneimittelDr. Dimitrios Chatsiproios; Dr. med. Klaus König; SAM®, Statistische Analysen...Completed
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
Shanghai Zhongshan HospitalRecruiting
-
Sarawak General HospitalUniversiti Sains Malaysia; Avantsar Sdn. Bhd.RecruitingPalmar-Plantar Erythrodysesthesia | Palmar-Plantar Erythrodysesthesia Due to Cytotoxic TherapyMalaysia
-
Dr. August Wolff GmbH & Co. KG ArzneimittelCompletedVaginal DrynessGermany
-
University of North Carolina, CharlotteTeva Branded Pharmaceutical Products R&D, Inc.CompletedMultiple SclerosisUnited States
-
Incyte CorporationCompletedCutaneous Lichen PlanusUnited States, Canada
-
Incyte CorporationRecruitingPrurigoUnited States, Spain, France, Poland, Germany, Belgium, Netherlands, Argentina, Italy, Canada, Chile, Brazil
-
Edesa Biotech Inc.JSS Medical Research Inc.Active, not recruitingAllergic Contact DermatitisUnited States, Canada